Contact
searchSearch
HMP Global
Login

News

News
Rucaparib Plus Nivolumab Shows Biomarker-Linked Activity in Advanced Biliary Tract Cancer
08/19/2026
Emily Estrada
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02...
08/19/2026
Oncology
News
Zanidatamab Plus Tislelizumab Improves Survival in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
06/10/2026
Emily Estrada
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01...
06/10/2026
Oncology
News
Five-Year Follow-up Confirms Survival Benefit With Nivolumab Plus Chemotherapy in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the...
02/12/2026
Oncology
News
Anbenitamab Plus Chemotherapy Improves Survival After Trastuzumab in HER2-Positive Gastric and Gastroesophageal Junction Cancer
01/21/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial...
01/21/2026
Oncology
News
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
News
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
News
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
News
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
News
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
News
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology

Recent News

News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use